Valeant Pharmaceuticals (VRX) Bull-Bear Debate Rages

Valeant Pharmaceuticals (VRX) PT, Estimates Cut at Jefferies after Dropping Philidor

Jefferies analyst David Steinberg lowered estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $172.00 (from $224.00) after the company dropped Philidor but maintained a Buy rating.

commented, "VRX severed ties with Philidor following allegations of improper business conduct and intense... More

Goldman Sachs Downgrades Valeant Pharmaceuticals (VRX) to Neutral

(Updated - November 2, 2015 8:42 AM EST)

Goldman Sachs downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral with a price target of $122 (prior $180). Analyst Gary Nachman thinks re-establishing confidence will be a long road.

"Given the events that have transpired very rapidly in recent weeks... More

Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday

Citron Research's Andrew Left is dialing back on what investors should expect when he updates his report on battered Valeant Pharma (NYSE: VRX) on Monday.

During Bill Ackman's 4-hour defense of Valeant on Friday, short seller Left tweeted: "$VRX has a... More

Valeant Pharma (VRX) Trades Near Lows Heading Into Weekend

Valeant Pharma (NYSE: VRX) fell to session lows in the final hour of trading. Earlier Citron said it plans to update its short report on Monday, claiming the company is "dirtier than has been reported." Concerns about the possible release of new information set... More

Citron Research says Valeant Pharma (VRX) has better chance than HLF of 'going to $0'

Citron Research says Valeant Pharma (NYSE: VRX) has better chance than HLF of 'going to $0'. Citron said it will have more details on Monday. Calls company 'dirtier' than anyone has reported.

... More

Bill Ackman said their average cost on Valeant Pharma (VRX) is $186

On Valeant Pharma (NYSE: VRX) call, Bill Ackman said their average cost is $186

Bill Ackman Said Fund 'Fully Invested'; 'Scraped Together Funds' to Buy Recent 2M Shares

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman said the fund is fully invested. Says he 'scraped together couple hundred million' to buy recent 2 million shares.

Bill Ackman Compares Valeant Pharma (VRX) to American Express (AXP) in 1960s; Notes Buffett Bought on Panic

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman disuses the 1960s soybean oil losses involving American Express (NYSE: AXP). Discusses how Warren Buffett got involved at that time, buying up all the stock that was being sold.

Bill Ackman said Valeant Pharma (VRX) worth $180-$240 Near-Term, $262-$350 Long-Term

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman said Valeant worth $180-$240 and worth $262-$350 longer term (2020).

Valeant (VRX) Trading at Less than 8X 2016 EPS Ex-Philidor - Ackman

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman said if all Philidor contributing elminted, stock trading at 8X 2016 EPS

Bill Ackman calls Valeant (VRX) Bausch & Lomb� 'best in the business'

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman calls the company's Bausch & Lomb 'best in the business' despite having past issues itself related to MoistureLoc. Salix also had some its own regulatory issues.

Ackman: Valeant's main problem is PR, not fraud

By Svea Herbst-Bayliss

BOSTON (Reuters) - Hedge fund mogul William Ackman told his investors on Friday that he was confident in his bet on Valeant Pharmaceuticals (NYSE: VRX)(NYSE: VRX) but faulted the company for a weak response to fraud allegations that have sunk its stock.

He said during a teleconference that Valeant had made a "meaningful mistake" of underinvesting in its public relations and offered an... More

Bill Ackman said the $100 million option on Philidor was for 'exclusivity' (VRX)

On the Valeant Pharma (NYSE: VRX) call, Bill Ackman said the $100 million option on Philidor was for 'exclusivity' and requested by Philidor, after speaking to former CFO.

Pre-Open Stock Movers 10/30: (CRAY) (YRCW) (LNKD) Higher; (AAN) (CTRL) (SCTY) Lower (more...)

VirtualScopics (NASDAQ: VSCP) 50.8% HIGHER; reported Q3 EPS of ($0.02), versus ($0.33) reported last year. Revenue for the quarter came in at $3.22 million, versus $2.74 million reported last year.

Amazon (AMZN) Should Distribute Drugs - Ackman

On its Valeant Pharma (NYSE: VRX) call, Bill Ackman suggests Amazon.com (NASDAQ: AMZN) should distribute drugs. He said the specialty pharmacy model is future, cutting out wholesalers.

Pershing Square Valeant Pharma (VRX) Conf. Call Up and Running after Technical Difficulties

After initially crashing on heavy volume, Bill Ackman's conference call on Valeant Pharma (NYSE: VRX) is up and running again after technical difficulties.

It can be found here: http://livestream.com/PershingSquare/events/4464622

Valeant Pharma (VRX) on Watch as Ahead of Pershing Square Conference Call

Down 7.6% currently, Valeant Pharma (NYSE: VRX) is on watch ahead of Bill Ackman's conference call, which is starting at 9:00AM ET.

During the call, Bill Ackman and other members of the Pershing Square investment team will address questions from investors... More

I Hope Bill Ackman Has Done More Research on Valeant (VRX) Than Herbalife: Herbalife (HLF)

Global nutrition company Herbalife (NYSE: HLF) today issued the following statement regarding a presentation by Bill Ackman:

I hope Bill Ackman has done more research on Valeant (NYSE: VRX) than he did on Herbalife, Target, Borders and JC Penny, said Alan Hoffman, executive vice president, global corporate affairs, Herbalife.

Herbalife

Valeant Pharma (VRX) Appoints Former U.S. Deputy AG Filip to Advise Ad Hoc Committee

Valeant Pharma (NYSE: VRX) announced that the ad hoc committee appointed by Valeant's board of directors has appointed former Deputy Attorney General of the United States Mark Filip of Kirkland & Ellis LLP to advise the committee in its review of allegations related to Valeant's... More

Evercore ISI's Raffat Provides Thoughts on Valeant Pharma (VRX)

Evercore ISI's Umer Raffat weighed in on Valeant Pharma (NYSE: VRX) following press reports last night on Philidor's drug dispensing practices and news this morning that Valeant is severing all ties to Philidor is a step in the right direction.

Raffat said he... More

Stocks slip but post best month in four years

By Lewis Krauskopf

(Reuters) - U.S. stock indexes finished with their strongest monthly performances in four years on Friday, even as they dipped for the day amid a mixed bag of earnings reports.

For October, all three major indexes posted their biggest percentage increases since October 2011, with the S&P 500 rising 8.3 percent, led by energy and materials, while a measure of volatility fell.

On Friday, CVS Health (NYSE: CVS) fell 4.8 percent to $98.78 after a disappointing profit forecast for 2016.

The S&P 500 energy index was the best performing sector, rising... More

BTIG Downgrades Valeant Pharmaceuticals (VRX) to Neutral

BTIG downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral.

The firm noted: We believe Valeant needs to sever its relationship with the specialty pharmacy Philidor and move on. Until that occurs, we can no longer have a positive view on the... More

Valeant Pharma (VRX) to Sever Ties with Philidor

Valeant Pharma (NYSE: VRX) announced that it is severing all ties with Philidor Rx Services, LLC, and that Philidor has informed Valeant that it will shut down operations as soon as possible, consistent with applicable laws.

"The newest allegations about activities at Philidor raise additional questions about the company's business practices," said J. Michael Pearson, Valeant's... More